Other languages Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Real-time Estimate Cboe BZX Other stock markets 09:30:22 2024-04-24 am EDT			5-day change	1st Jan Change
72.76 ^USD	-0.44%		+6.21%	-8.18%

Apr. 02	Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	MT
Apr. 01	Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	Apr. 02
Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	Apr. 01
Axsome Therapeutics Says Survey Shows Narcolepsy Symptoms Persist Despite Treatment	Mar. 25
Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	Mar. 25
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial	Mar. 25
Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in the SYMPHony Phase 3 Trial in Narcolepsy	Mar. 25
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	Mar. 19
Axsome Therapeutics Insider Sold Shares Worth $2,257,449, According to a Recent SEC Filing	Mar. 18
Sector Update: Health Care Stocks Lower Late Afternoon	Feb. 20
Sector Update: Health Care Stocks Softer Tuesday Afternoon	Feb. 20
Axsome Therapeutics Q4 Net Loss Widens, Revenue Rises; Shares Drop	Feb. 20
Axsome Therapeutics Q4 Net Loss Widens, Revenue Rises	Feb. 20
Axsome Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20
Axsome Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 20
Axsome Therapeutics Q3 Net Loss Widens, Revenue Rises	Nov. 06
Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06
Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference	23-10-24
Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors	23-10-11
Axsome Therapeutics Insider Sold Shares Worth $2,224,430, According to a Recent SEC Filing	23-09-18
Axsome Therapeutics' Q2 Net Loss Widens, Revenue Increases	23-08-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Other languages

Filters